Аннотация
Так называемые «атипичные» микроорганизмы, к числу которых принадлежит Chlamydophila pneumoniae, способны вызывать целый ряд острых инфекционных заболеваний верхних и нижних дыхательных путей и, прежде всего, внебольничную пневмонию. Кроме того, C. pneumoniae может играть роль в развитии таких неинфекционных заболеваний как бронхиальная астма и хроническая обструктивная болезнь лёгких. Сложности диагностики острой и хронической *C. pneumoniae*инфекции затрудняют установление истинной связи между данным возбудителем и тем или иным заболеванием. Хорошо известен круг антибактериальных препаратов, активных в отношении внутриклеточных микроорганизмов: макролиды (эритромицин, спирамицин, джозамицин, азитромицин, кларитромицин и др.), респираторные фторхинолоны (левофлоксацин, моксифлоксацин, гемифлоксацин), тетрациклины (доксициклин). Трудоёмкость этиологической диагностики «атипичной» инфекции в остром периоде заболевания, особенно при внебольничной пневмонии, ограничивает оптимизацию антибактериальной терапии.
-
1.
Kuo C.C., Jackson L.A., Campbell L.A., Grayston J.T. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev1995; 8:451-61.
-
2.
Koh W.P., Taylor M.B., Hughes K., et al. Seroprevalence of IgG antibodies against Chlamydia pneumoniae in Chinese, Malays and Asian Indians in Singapore. Int J Epidemiol 2002; 31:1001-7.
-
3.
Ferrari M., Poli A., Olivieri M., et al. Seroprevalence of Chlamydia pneumoniae antibodies in a young adult population sample living in Verona. European Community Respiratory Health Survey (ECRHS) Verona. Infection 2000; 28:38-41.
-
4.
Leowattana W., Mahanonda N., Bhuripanyo K., et al. Seroprevalence of Chlamydia pneumoniae infection in Thailand. J med Assoc Thai 2000; 83 Suppl 2:S1-S5.
-
5.
Blasi F., Tarsia P., Arosio C., et al. Epidemiology of Chlamydia pneumoniae. Clin Microbiol Infect 1998; 4 Suppl 4:S1-S6.
-
6.
Yang J, Hooper WC, Phillips DJ et al. Induction of proinflammatory cytokines in human lung epithelial cells during Chlamydia pneumoniae infection. infect immun 2003; 71:614–20.
-
7.
Halme S., Latvala J., Karttunen R., et al. Cell-mediated innune response during primary Chlamydia pneumoniae infection. Infect Immun 2000; 68:7156-8.
-
8.
Redecke V., Dalhoff K., Bohnet S., et al. Interaction of Chlamydia pneumoniae and human alveolar macrophages: infection and inflammatory response. Am J Respir Cell Mol Biol 1998; 19:721-7.
-
9.
Peeling R.W., Bailey R.L., Conway D.J., et al. Antibody response to the 60-kDa chlamydial heat-shock protein is associated with scarring trachoma. J Infect Dis 1998; 177:256-9.
-
10.
Peeling R.W., Kimani J., Plummer F., et al. Antibody to chlamydial hsp60 predicts an increased risk for chlamydial pelvic inflammatory disease. J Infect Dis 1997; 175:1153-8.
-
11.
Toye B., Laferriere C., Claman P., et al. Association between antibody to the chlamydial heat-shock protein and tubal infertility. J Infect Dis 1993; 168:1236-40.
-
12.
Brunham R.C., Peeling R., Maclean I., Kosseim M.L., Paraskevas M. Chlamydia trachomatis-associated ectopic pregnancy: serologic and histologic correlates. J Infect Dis 1992; 165:1076-81.
-
13.
Huittinen T., Hahn D., Anttila T., et al. Host immune response to Chlamidia pneumoniae heat shock protein 60 is assotiated with asthma. Eur Respir J 2001; 17:1078- 82.
-
14.
Mayr M., Metzler B., Kiechl S., et al. Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamidia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 1999; 99:1560-6.
-
15.
Тартаковский И.С. Современные подходы к диагностике атипичных пневмоний. Клиническая Микробиология и Антимикробная Химиотерапия 2000; 1:60-8.
-
16.
Dowell S.F., Peeling R.W., Boman J., et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001;33:492-503.
-
17.
Blasi F., Tarsia P., Arosio C., Fagetti L., Allegra L. Epidemiology of Chlamydia pneumoniae. Clin Microbiol Infect 1998;4:1-6.
-
18.
Blasi F. Atipical pathogens and respiratory tract infections. Eur Respir J 2004; 24:171-82.
-
19.
Tondella M.L.C., Talkington D.F., Holloway B.P., et al. Development and evaluation of Real-time PCR-based fluorescence assays for detection of Chlamydia pneumoniae. J Clin Microbiol 2002; 40:575–83.
-
20.
Miyashita N., Obase Y., Fukuda M., et al. Evaluation of the diagnostic usefulness of real-time PCR for detection of Chlamydophila pneumoniae in acute respiratory infections. J Infect Chemother 2007; 13:183-7.
-
21.
File T.M. Jr., Tan J.S., Plouffe J.F. The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. Infect Dis Clin North Am 1998; 12:569-92.
-
22.
Niederman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-54.
-
23.
Almirall J., Morato I., Riera F., et al. Incidence of community-acquired pneumonia and Chlamydia pneumoniae infection: a prospective multicentre study. Eur Respir J 1993; 6:14-8.
-
24.
Marrie T.J., Peeling R.W., Fine M.J., Singer D.E., Coley C.M., Kapoor W.N. Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996; 101:508-15.
-
25.
File T.M. Jr., Segreti J., Dunbar L., et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41:1965–72.
-
26.
Sopena N., Sabria-Leal M., Pedro-Botet M.L., et al. Comparative study of the clinical presentation of Legionella pneumonia and other community-acquired pneumonias. Chest 1998; 113:1195–200.
-
27.
Aubertin J., Dabis F., Fleurette J., et al. Prevalence of legionellosis among adults: a study of community-acquired pneumonia in France. Infection 1987; 15:328-31.
-
28.
Steinhoff D., Lode H., Ruckdeschel G., et al. Chlamydia pneumoniae as a cause of community-acquired pneumonia in hospitalized patients in Berlin. Clin Infect Dis 1996; 22:958-64.
-
29.
Lieberman D., Lieberman D., Porath A. Seasonal variation in community-acquired pneumonia. Eur Respir J 1996; 9:2630-4.
-
30.
Neill A.M., Martin I.R., Weir R., et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996; 51:1010-6.
-
31.
Bohte R., van Furth R., van den Broek P.J. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995; 50:543-7.
-
32.
Chaudhry R., Nazima N., Dhawan B., Kabra S.K. Prevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community acquired pneumonia. Indian J Pediatr 1998; 65:717-21.
-
33.
Bochud PY, Moser F, Erard P, et al. Communityacquired pneumonia. A prospective outpatient study. Medicine (Baltimore) 2001; 80:75-87.
-
34.
El Solh A.A., Sikka P., Ramadan F., Davies J. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001; 163:645-51.
-
35.
Heiskanen-Kosma T., Korppi M., Jokinen C., et al. Etiology of childhood pneumonia: serologic results of a prospective, population-based study. Pediatr Infect Dis J 1998; 17:986-91.
-
36.
Principi N., Esposito S., Blasi F., Allegra L. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin Infect Dis 2001; 32:1281-9.
-
37.
Wubbel L., Muniz L., Ahmed A., et al. Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr Infect Dis J 1999; 18:98-104.
-
38.
Cunha B.A. The atypical pneumonias: clinical diagnosis and importance. Clin Microbiol Infect 2006; 12:12-24.
-
39.
Ishida T., Miyashita N., Nakahama C. Clinical differentiation of atypical pneumonia using Japanese guidelines. Respirology 2007; 12:104-10.
-
40.
Daian C.M., Wolff A.H., Bielory L. The role of atypical organisms in asthma. Allergy Asthma Proc 2000; 21:107- 11.
-
41.
Hahn D.L., Dodge R.W., Golubjatnikov R. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA 1991; 266:225-30.
-
42.
Hahn D.L. Chlamydia pneumoniae, asthma and COPD: what is the evidence? Ann Allergy Asthma Immunol 1999; 83:271-88.
-
43.
Esposito S., Principi N. Asthma in children: are chlamydia or mycoplasma involved? Paediatr Drugs 2001; 3:159-68.
-
44.
Isaacs D., Joshi P. Respiratory infections and asthma. Med J Aust 2002; 177(Suppl):S50-1.
-
45.
Von Hertzen L.C. Role of persistent infection in the control and severity of asthma: focus on Chlamydia pneumoniae. Eur Respir J 2002; 19:546-56 .
-
46.
Von Hertzen L.C. Chlamydia pneumoniae and its role in chronic obstructive pulmonary disease. Ann Med 1998; 30:27-37.
-
47.
Blasi F., Legnani D., Lombardo V.M., et al. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993; 6:19-22.
-
48.
Blasi F., Damato S., Cosentini R., et al. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax 2002; 57:672-6.
-
49.
Von Hertzen L.C., Isoaho R., Leinonen M., et al. Chlamydia pneumoniae antibodies in chronic obstructive pulmonary disease. Int J Epidemiol 1996; 25:658-64.
-
50.
Park S.J., Lee Y.C., Rhee Y.K., et al. Seroprevalence of Mycoplasma pneumoniae and Chlamydia pneumoniae in stable asthma and chronic obstructive pulmonary disease. J Korean Med Sci 2005; 20:225-8.
-
51.
Diederen B.M., van der Valk P.D., Kluytmans J.A., et al. The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007; 30:240-4.
-
52.
Juvonen R., Bloigu A., Paldanius M., et al. Acute Chlamydia pneumoniae infections in asthmatic and nonasthmatic military conscripts during a non-epidemic period. Clin Microbiol Infect 2008; 14:207-12.
-
53.
Esposito S., Blasi F., Bosis S., et al. Aetiology of acute pharyngitis: the role of atypical bacteria. Journal of Medical Microbiology 2004; 53:645-51.
-
54.
Lee R.E., Kaza S., Plano G.V., et al. The role of atypical bacteria in chronic rhinosinusitis. Otolaryngol Head Neck Surg 2005; 133:407-10.
-
55.
Lode H.M. Managing community-acquired pneumonia: a European perspective. Respir Med 2007; 101:1864-73.
-
56.
Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious diseases Society of America/American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Diseases 2007; 44:S27-72.
-
57.
Pavié G.J., Prida C.J.M., Díaz F.A., et al. Assessment of the management of community-acquired pneumonia in adults outpatients. Rev Med Chil 2005; 133:1322-30.
-
58.
Segreti J., House H.R., Siegel R.E. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am J Med 2005; 118:21S-28S.
-
59.
Arnold F.W., Summersgill J.T., Lajoie A.S., et al. A worldwide perspective of atypical pathogens in communityacquired pneumonia. Am J Respir Crit Care Med 2007; 175:1086-93.
-
60.
Gotfried M.H. Appropriate outpatient macrolide use in community-acquired pneumonia. J Am Acad Nurse Pract 2004; 16:146-50.
-
61.
Woodhead M., Blasi F., Ewig S., et al. Guidelines for the Management of adult lower respiratory tract infections. Eur Respir J 2005; 26:1138-80.
-
62.
Drehobl M.A., De Salvo M.C., Lewis D.E., et al. Singledose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005; 128:2230-7.
-
63.
Amayasu H., Yoshida S., Ebana S., et al. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000; 4:594-8.
-
64.
Black P.N., Blasi F., Jenkins C.R., et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae Am J Respir Crit Care 2001; 164:536-41.
-
65.
Kraft M., Cassell G.H., Pak J., et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma. Effect of Clarithromycin. Chest 2002; 121:1782-8.
-
66.
Ekici A., Ekici M., Erdemoglu A.K. Effect of azithromycin on the severity of bronchial hyper responsiveness in patients with mild asthma J Asthma 2002; 39:181-5.
-
67.
Kostadima E., Tsiodras S., Alexopoulos E.I., et al. Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma. Eur Respir J 2004; 23:714-7.
-
68.
Hahn D.L., Plane M.B., Mahdi O.S., et al. secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma. PLoS Clin Trials 2006;1:e11.